Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin E Dose Increases Linked To Rise In Risk Of Death – Study

This article was originally published in The Tan Sheet

Executive Summary

Negative results from a vitamin E study showing high doses of the supplement may lead to a greater risk of all-cause mortality increase industry anticipation of findings from ongoing prospective antioxidant trials
Advertisement

Related Content

Nonprescription survey
Vitamin E Study Rules Out Cancer Prevention, Suggests Heart Risk Link
Vitamin E Not Linked To CV Risk Reduction – Women’s Health Study
Vitamin Market Weakness Paves Way For Acquisitions – NBTY
Vitamin E editorial
Supplemental Vitamin E Reduces ALS Mortality Risk – Study
NBTY Reports High Rexall Brand Returns In Fourth Quarter
Antioxidant Supplementation Found To Be Beneficial In Men, But Not Women
Vitamin E Industry Websites Tout Benefits, Counter Meta-Analysis Findings
Lancet Meta-Analysis Deconstructs Vitamin Benefits In Cancer Cases

Topics

Advertisement
UsernamePublicRestriction

Register

PS097529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel